Search
Filters
Clear All
  • 8

Phase

  • 2
  • 6
  • 8
  • 7

Found 8 Sarcoma trials

A listing of Sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479 NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

S
Sandeep Batra, MD
All genders
This randomized phase II trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body.
Learn More

A COG Soft Tissue Sarcoma Biology and Banking Protocol

S
Sandeep Batra, MD
50-100 years
All genders
The purpose of this study is to better diagnose certain types of cancer.
Learn More

A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI Torisel NSC# 683864 IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

S
Sandeep Batra, MD
All genders
The purpose of this study is to compare the event-free survival of patients with IR RMS treated with surgery, radiotherapy and VAC alternating with VI (VAC/VI) to that of patients treated with surgery, radiotherapy and VAC/VI plus temsirolimus (TORI).
Learn More

Title: A Phase 2 multicenter open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS) non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)

K
Kristy Pilbeam
1-18 years
All genders
The purpose of this study is to assess of activity of eribulin mesylate in pediatric subjects with relapsed/refractory RMS, NRSTS or EWS.
Learn More

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults With Refractory Sarcomas Wilms Tumor and Other Rare Tumors

S
Sandeep Batra, MD
2-30 years
All genders
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
Learn More

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

M
Melissa Bear, MD
12-100 years
All genders
Phase 1/2
Interventional
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that that has either come back (relapsed) or does not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and …
Learn More

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

S
Sandeep Batra, MD
1-21 years
All genders
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has …
Learn More

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

M
Melissa Bear, MD
12-30 years
All genders
Phase 1/2
Interventional
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of …
Learn More